A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Registration Number
- NCT02588261
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Brief Summary
The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
This study also assessed Overall survival (OS); Overall response rate (ORR) as assessed by IRR; PFS as assessed by the investigator; Disease control rate (DCR) as assessed by IRR; Duration of Response (DOR) by IRR; Safety of ASP8273; and Quality of Life (QOL) and patient-reported outcome (PRO) parameters.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 530
-
Subject agrees not to participate in another interventional study while on treatment.
-
Female subject must either:
- Be of nonchildbearing potential: postmenopausal (defined as at least 1 year without any menses) prior to Screening, or documented surgically sterile
- Or, if of childbearing potential: Agree not to try to become pregnant during the study and for 28 days after the final study drug administration; And have a negative serum pregnancy test at Screening; And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control (at least 1 of which must be a highly effective method and one must be a barrier method) starting at Screening and throughout the study period and for 28 days after the final study drug administration.
-
Female subject must not be breastfeeding at Screening or during the study period, and for 28 days after the final study drug administration.
-
Female subject must not donate ova starting at Screening and throughout the study period, and for 28 days after the final study drug administration.
-
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
-
Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
-
Subject has Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
-
Subject has histologically confirmed locally advanced, metastatic or unresectable Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with mixed histology are eligible if adenocarcinoma is the predominant histology.
-
Subject has predicted life expectancy ≥ 12 weeks in the opinion of the investigator.
-
Subject must meet all of the following criteria on the laboratory tests that will be analyzed centrally within 7 days prior to the first dose of study drug. In case of multiple laboratory data within this period, the most recent data should be used.
- Neutrophil count > 1,000/mm3
- Platelet count ≥ 7.5 x 104 /mm3
- Hemoglobin > 8.0 g/dL
- Serum creatinine ˂ 2.0 x upper limit of normal (ULN) or an estimated glomerular filtration rate (eGFR) of > 50 mL/min as calculated by the Cockcroft Gault Method
- Total bilirubin ˂1.5 x ULN (except for subjects with documented Gilbert's syndrome)
- AST and ALT ˂ 3.0 x ULN or ≤ 5 x ULN if subject has documented liver metastases
- Serum sodium level is ≥ 130 mmol/L
-
Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation, by local or central testing on examination of a NSCLC FFPE specimen (archival or fresh biopsy). Subjects harboring both exon 19 deletion and exon 21 L858R mutations are not eligible. A tissue sample from the same block used to determine eligibility by local testing should be available to send to the central lab for confirmatory testing. Subjects randomized based on local results indicating presence of EGFR mutation may remain on study if central results are discordant.
-
Subject must have at least 1 measureable lesion based on RECIST V1.1. Previously irradiated lesions will not be considered as measurable lesions.
- Subject has received intervening anticancer treatment or previous treatment with chemotherapy for metastatic disease other than palliative local radiation to painful bone metastases completed at least 1 week prior to the first dose of study drug. The administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it has finalized ≥ 6 months before the first dose of study drug.
- Subject has received a prior treatment with a therapeutic agent targeting EGFR (e.g., afatinib, dacomitinib, ASP8273, etc).
- Subject has received investigational therapy within 28 days or 5 half-lives prior to the first dose of study drug.
- Subject has received radiotherapy within 1 week prior to the first dose of study drug. If the subject received radiotherapy > 1 week prior to study treatment, the irradiated lesion cannot be the only lesion used for evaluating response.
- Subject has symptomatic central nervous system (CNS) metastasis. Subject with previously treated brain or CNS metastases are eligible provided that the subject has recovered from any acute effects of radiotherapy, does not have brain metastasis related symptoms, is not requiring systemic steroids for at least 2 weeks prior to study drug administration, and any whole brain radiation therapy was completed at least 4 weeks prior to study drug administration, or any stereotactic radiosurgery (SRS) was completed at least 2 weeks prior to study drug administration. Steroid inhaler use or ointment treatment for other concomitant medical disease is permitted.
- Subject has received blood transfusions or hematopoietic factor therapy within 14 days prior to the first dose of study drug.
- Subject has had a major surgical procedure (other than a biopsy) within 14 days prior to the first dose of study drug, or one is planned during the course of the study.
- Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection.
- Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP8273, erlotinib or gefitinib.
- Subject has evidence of an active infection requiring systemic therapy within 14 days prior to the planned first dose of study drug.
- Subject has severe or uncontrolled systemic diseases including uncontrolled hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.
- Subject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.
- Subject has ongoing cardiac arrhythmia that is Grade ≥ 2 or uncontrolled atrial fibrillation of any grade.
- Subject currently has Class 3 or 4 New York Heart Association congestive heart failure.
- Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the planned first dose of study drug.
- Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3 months prior to the planned first dose of study drug.
- Subject has concurrent corneal disorder or any ophthalmologic condition which, in the investigator's opinion, makes the subject unsuitable for study participation (i.e., advanced cataracts, glaucoma).
- Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.
- Subject has another past or active malignancy which requires treatment. Prior carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.
- Subject has any condition which, in the investigator's opinion, makes the subject unsuitable for study participation.
- Subject has received potent CYP 3A4 inhibitors within 7 days prior to first dose of study drug or proton pump inhibitors such as omeprazole within 14 days prior to first dose of study drug.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ASP8273 naquotinib mesilate Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up). erlotinib or gefitinib Erlotinib Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up). erlotinib or gefitinib Gefitinib Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR) From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months) PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by IRR. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available.
- Secondary Outcome Measures
Name Time Method Percentage of Deaths From date of randomization up to data cut-off date 21 Dec 2017 (approximately 22 months) All events of death after the first study drug administration were included.
Percentage of Participants With Objective Response (OR) From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months) Percentage of participants with OR was defined as the proportion of participants with best overall response as complete response (CR) or partial response (PR) without confirmation based on the RECIST v1.1 as assessed by the blinded IRR. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.
PFS as Assessed by the Investigator From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months) PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on RECIST V1.1, as assessed by local investigator. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available.
Percentage of Participants With Disease Control From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months) Percentage of participants with disease control was defined as the proportion of participants whose best overall response was rated as CR, PR or stable disease (SD) among all analyzed participants based on RECIST V1.1. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug.
Duration of Response (DOR) From date of first response up to data cut-off date 09 May 2017 (approximately 15 months) DOR was defined as the time from the date of the first response CR/PR (whichever was first recorded) as assessed by IRR to the date of radiographical progression or date of censoring. If a participant had not progressed, the participant was censored at the date of last radiological assessment or at the date of first CR/PR if no post-baseline radiological assessment was available. Results are based Kaplan-Meier estimate.
Number of Participants With Adverse Events (AEs) From first dose of study drug up to 30 days after last dose of study drug taken up to data cut-off 09 May 2017 Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization.
Functional Assessment of Cancer Therapy - EGFR Inhibitors Subscale (FACT-EGFRI-18) Questionnaire Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months) ACT-EGFRI-18 is an 18-item Likert-scaled questionnaire, used to assess the effect of EGFR inhibitors on quality of life (QoL). The questionnaire is arranged in three HRQL dimensions: physical (seven items), social/emotional (six items), and functional well-being (five items). The response scores ranged from 0 to 4, and the response categories include "not at all", "a little bit", "somewhat", "quite a bit", and "very much." Negatively worded items (e.g., "My skin bleeds easily "or "My skin condition affects my mood") are reverse-scored, so that participants who experience a higher impact of symptom burden on HRQL receive a lower score (range 0-72).
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 (EORTC-QLQ-LC13) Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months) The EORTC-QLQ-LC13 is a validated module of the EORTC-QLQ-Core 30, which includes module items that evaluate symptoms such as cough, hemoptysis, shortness of breath, sore mouth or tongue, dysphagia, tingling hands or feet, hair loss and pain. The total score for the questionnaire ranges from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months) EORTC-QLQ-LC30 is a 30-item cancer-specific questionnaire with multitrait scaling was used to create five functional domain scales: Physical, Role, Emotional, Social and Cognitive; two items evaluate global QoL; in addition, three symptom scales assess Fatigue, Pain and Emesis; and six single items assess other symptoms. The total score ranges from 0 to 100, with a high score for a functional scale representing a high/healthy level of functioning and a high score for a symptom scale or item representing a high level of symptomatology or problems.
EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months) The EQ-5D is a generic preference-based measure that indirectly measures the utility for health that generates an index-based summary score based upon societal preference weights. The EQ-5D-5L consists of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale (VAS) for health status. Each item has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status).
Trial Locations
- Locations (167)
Site US10025
🇺🇸Fountain Valley, California, United States
Site US10003
🇺🇸Santa Monica, California, United States
Site US10013
🇺🇸Aventura, Florida, United States
Site US10037
🇺🇸Scarborough, Maine, United States
Site US10033
🇺🇸Los Angeles, California, United States
Site US10050
🇺🇸Atlanta, Georgia, United States
Site UA38009
🇺🇦Uzhgorod, Zakarpats'ka Oblast', Ukraine
Site AU61002
🇦🇺Fitzroy, Victoria, Australia
Site CL56001
🇨🇱Santiago, Región Metropolitana De Santia, Chile
Site US10012
🇺🇸Mount Kisco, New York, United States
Site US10027
🇺🇸Rochester, Minnesota, United States
Site DE49006
🇩🇪Wurzburg, Bayern, Germany
Site AU61003
🇦🇺Randwick, New South Wales, Australia
Site US10018
🇺🇸Whittier, California, United States
Site US10031
🇺🇸Oxnard, California, United States
Site IT39013
🇮🇹Lucca, Italy
Site CL56002
🇨🇱Vina del Mar, Valparaíso, Chile
Site FR33007
🇫🇷Pierre Benite, Rhône, France
Site BE32002
🇧🇪Gent, West-Vlaanderen, Belgium
Site IT39012
🇮🇹Piacenza, Italy
Site JP81024
🇯🇵Kobe, Hyogo, Japan
Site DE49003
🇩🇪Gauting, Bayern, Germany
Site CL56007
🇨🇱Vina del Mar, Valparaíso, Chile
Site FR33011
🇫🇷Suresnes, Hauts-de-Seine, France
Site FR33006
🇫🇷Grenoble, Isère, France
Site JP81005
🇯🇵Miyakojima-ku, Osaka, Japan
Site KR82004
🇰🇷Suwon-si, Gyeonggi-do, Korea, Republic of
Site US10011
🇺🇸Lacey, Washington, United States
Site JP81008
🇯🇵Kurume, Hukuoka, Japan
Site AU61007
🇦🇺Woolloongabba, Queensland, Australia
Site KR82016
🇰🇷Suwon-si, Gyeonggido [Kyonggi-do], Korea, Republic of
Site DE49007
🇩🇪Kassel, Hessen, Germany
Site US10048
🇺🇸Saint Petersburg, Florida, United States
Site DE49005
🇩🇪Karlsruhe, Baden-Württemberg, Germany
Site AU61005
🇦🇺Adelaide, South Australia, Australia
Site CA15006
🇨🇦Toronto, Ontario, Canada
Site FR33010
🇫🇷Pessac, Gironde, France
Site HU36006
🇭🇺Szombathely, Vas, Hungary
Site JP81018
🇯🇵Matsuyama, Ehime, Japan
Site IT39009
🇮🇹Rozzano, Lombardia, Italy
Site JP81006
🇯🇵Okayama, Japan
Site NL31006
🇳🇱Alkmaar, Noord-Holland, Netherlands
Site IT39004
🇮🇹Monza, Lombardia, Italy
Site FR33003
🇫🇷Creteil, Ilej-de-France, France
Site KR82013
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site US10046
🇺🇸Milwaukee, Wisconsin, United States
Site AU61008
🇦🇺East Melbourne, Victoria, Australia
Site DE49008
🇩🇪Freiburg, Baden-Württemberg, Germany
Site JP81013
🇯🇵Hiroshima, Hirosima [Hiroshima], Japan
Site PT35104
🇵🇹Lisbon, Lisboa, Portugal
Site RO40004
🇷🇴Floresti, Cluj, Romania
Site IT39015
🇮🇹Brescia, Italy
Site JP81004
🇯🇵Tokyo, Tôkyô [Tokyo], Japan
Site JP81001
🇯🇵Sunto-gun, Sizuoka [Shizuoka], Japan
Site PE51004
🇵🇪San Isidro, Lima, Peru
Site JP81002
🇯🇵Osaka-sayama, Ôsaka [Osaka], Japan
Site KR82009
🇰🇷Jinju-si, Gyeongsangnamdo, Korea, Republic of
Site KR82011
🇰🇷Ulsan, Ulsan Gwang'yeogsi, Korea, Republic of
Site SG65001
🇸🇬Singapore, Central Singapore, Singapore
Site RO40001
🇷🇴Craiova, Dolj, Romania
Site RO40010
🇷🇴Craiova, Dolj, Romania
Site TW88601
🇨🇳Tainan, Taiwan
Site UA38005
🇺🇦Kryvyi Rih, Dnipropetrovs'ka Oblast', Ukraine
Site KR82006
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site RU70017
🇷🇺Ufa, Bashkortostan, Russian Federation
Site PE51001
🇵🇪Cercado De Lima, Arequipa, Peru
Site PT35103
🇵🇹Coimbra, Portugal
Site ES34017
🇪🇸Valencia, Spain
Site KR82003
🇰🇷Jeonju, Jeonrabugdo[Chollabuk-do], Korea, Republic of
Site ES34005
🇪🇸Sevilla, Spain
Site ES34016
🇪🇸Madrid, Spain
Site TH66001
🇹🇭Bangkok, Krung Thep Maha Nakhon [Bangkok], Thailand
Site UA38001
🇺🇦Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine
Site RU70001
🇷🇺Saint Petersburg, Russian Federation
Site TW88605
🇨🇳Taichung City, Taichung, Taiwan
Site ES34003
🇪🇸Barcelona, Catalunya, Spain
Site RO40012
🇷🇴Bucuresti, Romania
Site ES34010
🇪🇸Malaga, Málaga, Spain
Site UA38008
🇺🇦Ivano-Frankivsk, Ivano-Frankivs'ka Oblast', Ukraine
Site ES34008
🇪🇸San Sebastian, Guipuzcoa, Guipúzcoa, Spain
Site TW88603
🇨🇳Taichung, Taiwan
Site TH66012
🇹🇭Bangkok, Krung Thep Maha Nakhon [Bangkok], Thailand
Site ES34004
🇪🇸Ourense, Spain
Site TW88609
🇨🇳Taipei, Taiwan
Site TH66006
🇹🇭Songkla, Thailand
Site US10034
🇺🇸Boston, Massachusetts, United States
Site US10030
🇺🇸Minneapolis, Minnesota, United States
Site TW88607
🇨🇳Taoyuan Hsien, Taoyuan, Taiwan
Site HU36001
🇭🇺Budapest, Hungary
Site MY60001
🇲🇾Kuantan Pahang, Pahang, Malaysia
Site FR33004
🇫🇷Tours, Indre-et-Loire, France
Site FR33009
🇫🇷Saint Priest en Jarez, Loire, France
Site RO40008
🇷🇴Timisoara, Timis, Romania
Site TH66002
🇹🇭Chiang Rai, Thailand
Site TH66004
🇹🇭Khon Kaen, Thailand
Site GB44001
🇬🇧Liverpool, Wirral, United Kingdom
Site HU36003
🇭🇺Tatabanya, Tatabánya, Hungary
Site MY60002
🇲🇾Georgetown, Pulau Pinang, Malaysia
Site HU36007
🇭🇺Budapest, Hungary
Site HU36002
🇭🇺Szekesfehervar, Fejér, Hungary
Site PT35101
🇵🇹Amadora, Lisboa, Portugal
Site HU36004
🇭🇺Farkasgyepu, Veszprém, Hungary
Site PE51008
🇵🇪Miraflores, Lima, Peru
Site PT35102
🇵🇹Lisboa, Portugal
Site MY60004
🇲🇾Kuching, Sarawak, Malaysia
Site RO40006
🇷🇴Sibiu, Romania
Site SG65002
🇸🇬Singapore, Central Singapore, Singapore
Site TW88604
🇨🇳Tainan, Taiwan
Site GB44002
🇬🇧Middlesex, Hertfordshire, United Kingdom
Site NL31001
🇳🇱Arnhem, Gelderland, Netherlands
Site TH66011
🇹🇭Chom Thong, Chiang Mai, Thailand
Site US10009
🇺🇸Nashville, Tennessee, United States
Site US10023
🇺🇸Nashville, Tennessee, United States
Site IT39003
🇮🇹Bergamo, Italy
Site IT39002
🇮🇹Cremona, Italy
Site IT39014
🇮🇹Milano, Italy
Site JP81017
🇯🇵Osakasayama-shi, Hukuoka [Fukuoka], Japan
Site JP81012
🇯🇵Sendai, Miyagi, Japan
Site JP81022
🇯🇵Niigata, Japan
Site JP81020
🇯🇵Osakasayama-shi, Osaka, Japan
Site ES34006
🇪🇸Madrid, Spain
Site ES34015
🇪🇸Valencia, Spain
Site IT39008
🇮🇹Roma, Italy
Site ES34002
🇪🇸Valencia, Spain
Site US10036
🇺🇸La Jolla, California, United States
Site US10029
🇺🇸Beverly Hills, California, United States
Site US10051
🇺🇸Loma Linda, California, United States
Site US10052
🇺🇸Redondo Beach, California, United States
Site US10042
🇺🇸Baton Rouge, Louisiana, United States
Site US10047
🇺🇸Glenwood Springs, Colorado, United States
Site US10045
🇺🇸Albuquerque, New Mexico, United States
Site US10021
🇺🇸Bethlehem, Pennsylvania, United States
Site AU61004
🇦🇺Footscray, Victoria, Australia
Site CA15002
🇨🇦Montreal, Quebec, Canada
Site FR33012
🇫🇷Bayonne, Pyrénées-Atlantiques, France
Site DE49004
🇩🇪Köln, Nordrhein-Westfalen, Germany
Site IT39011
🇮🇹Aviano, Pordenone, Italy
Site JP81015
🇯🇵Kanazawa, Isikawa [Ishikawa], Japan
Site JP81014
🇯🇵Sapporo, Hokkaidô, Japan
Site JP81016
🇯🇵Kurashiki, Okayama, Japan
Site JP81021
🇯🇵Hirakata, Ôsaka [Osaka], Japan
Site JP81010
🇯🇵Yokohama, Kanagawa, Japan
Site JP81019
🇯🇵Sunto-gun, Shizuoka, Japan
Site KR82005
🇰🇷Cheongiu, Chungcheongbugdo, Korea, Republic of
Site JP81023
🇯🇵Wakayama, Japan
Site KR82017
🇰🇷Bundang, Gyeonggido, Korea, Republic of
Site KR82008
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site KR82002
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site KR82007
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site KR82015
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site KR82010
🇰🇷Busan Gwang'yeogsi, Korea, Republic of
Site RO40007
🇷🇴Ploiesti, Prahova, Romania
Site RU70012
🇷🇺Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation
Site RU70016
🇷🇺Nalchik, Kabardino-Balkarskaya Respublika, Russian Federation
Site RU70009
🇷🇺Magnitogorsk, Chelyabinskaya Oblast', Russian Federation
Site RU70008
🇷🇺Pyatigorsk, Stavropol'skiy Kray, Russian Federation
Site TW88606
🇨🇳Kaohsiung, Taiwan
Site TW88608
🇨🇳Taipei, Taiwan
Site TW88611
🇨🇳Taipei, Taiwan
Site UA38006
🇺🇦Chernivtsi, Chernivets'ka Oblast', Ukraine
Site JP81025
🇯🇵Yokohama, Kanagawa, Japan
Site KR82001
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Site KR82014
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Site GB44003
🇬🇧Sheffield, United Kingdom
Site UA38007
🇺🇦Lutsk, Volyns'ka Oblast', Ukraine
Site UA38004
🇺🇦Lviv, L'vivs'ka Oblast', Ukraine
Site UA38003
🇺🇦Uzhgorod, Zakarpats'ka Oblast', Ukraine